Relugolix, Enzalutamide, and Radiation Therapy for Very High Risk Prostate Cancer
Phase 2
50
about 8.2 years
18+
Male only
1 site in IL
What this study is about
This trial is testing whether relugolix and enzalutamide, combined with radiation therapy, are effective in treating very high risk prostate cancer. Relugolix prevents testosterone release to slow tumor growth, while enzalutamide blocks androgen receptors on prostate cells. Radiation therapy uses targeted energy to kill cancer cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Fluorine F 18 Piflufolastat
- 2.Questionnaire Administration
- 3.Receive Image Guided Radiation Therapy
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
enzalutamide, relugolix
oral (Oral Tablet)
Secondary: Disease-free survival
biopsy, diagnostic, imaging, radiation